MX2017013384A - Composiciones que comprenden adamts13 para el uso en metodos para la recanalizacion de los vasos sanguineos ocluidos en un infarto. - Google Patents
Composiciones que comprenden adamts13 para el uso en metodos para la recanalizacion de los vasos sanguineos ocluidos en un infarto.Info
- Publication number
- MX2017013384A MX2017013384A MX2017013384A MX2017013384A MX2017013384A MX 2017013384 A MX2017013384 A MX 2017013384A MX 2017013384 A MX2017013384 A MX 2017013384A MX 2017013384 A MX2017013384 A MX 2017013384A MX 2017013384 A MX2017013384 A MX 2017013384A
- Authority
- MX
- Mexico
- Prior art keywords
- infarction
- methods
- blood vessels
- adamts13
- recanalization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con métodos para la recanalización de vasos sanguíneos ocluidos en un paciente que tiene un infarto. El método incluye una etapa de administrar al paciente una cantidad terapéuticamente efectiva de la proteína ADAMTS13 aislada a dosificaciones particulares e intervalos de tiempo después de la detección del infarto. Como se describe en la presente, ADAMTS13 recanaliza ventajosamente los vasos sanguíneos ocluidos y reduce el tamaño del infarto, aun cuando se administra un periodo prolongado después de la oclusión estable. Por lo tanto, tales métodos y composiciones son útiles para el tratamiento de infartos causados por la oclusión de vasos sanguíneos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562166586P | 2015-05-26 | 2015-05-26 | |
| PCT/US2016/034353 WO2016191565A1 (en) | 2015-05-26 | 2016-05-26 | Compositions comprising adamts13 for use in methods for the recanalization of occluded blood vessels in an infarction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013384A true MX2017013384A (es) | 2017-12-07 |
Family
ID=53784248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013384A MX2017013384A (es) | 2015-05-26 | 2016-05-26 | Composiciones que comprenden adamts13 para el uso en metodos para la recanalizacion de los vasos sanguineos ocluidos en un infarto. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180110842A1 (es) |
| EP (1) | EP3302533A1 (es) |
| JP (2) | JP6877356B2 (es) |
| KR (1) | KR20180006376A (es) |
| CN (1) | CN107635577A (es) |
| AU (2) | AU2016268389A1 (es) |
| BR (1) | BR112017025142A2 (es) |
| CA (1) | CA2979940A1 (es) |
| EA (1) | EA201792130A1 (es) |
| GB (1) | GB201510870D0 (es) |
| HK (1) | HK1249863A1 (es) |
| MX (1) | MX2017013384A (es) |
| WO (1) | WO2016191565A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021198781A2 (en) | 2020-04-02 | 2021-10-07 | Takeda Pharmaceutical Company Limited | Adamts13 variant, compositions, and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539757A (ja) * | 2006-06-16 | 2009-11-19 | バクスター・インターナショナル・インコーポレイテッド | 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物 |
| JP5254973B2 (ja) * | 2007-06-22 | 2013-08-07 | 一般財団法人化学及血清療法研究所 | 新規ａｄａｍｔｓ−１３改変体 |
| EP2288377A1 (en) * | 2008-05-12 | 2011-03-02 | Immune Disease Institute | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction |
| US8623352B2 (en) * | 2009-09-21 | 2014-01-07 | Baxter International Inc. | Stabilized liquid and lyophilized ADAMTS13 formulations |
| CN103566362B (zh) * | 2012-07-21 | 2015-07-29 | 复旦大学 | 重组adamts13在制备脑出血药物中的用途 |
| AU2013203062C1 (en) * | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
-
2015
- 2015-06-19 GB GBGB1510870.7A patent/GB201510870D0/en not_active Ceased
-
2016
- 2016-05-26 EP EP16729425.5A patent/EP3302533A1/en not_active Withdrawn
- 2016-05-26 US US15/572,681 patent/US20180110842A1/en not_active Abandoned
- 2016-05-26 WO PCT/US2016/034353 patent/WO2016191565A1/en active Application Filing
- 2016-05-26 CN CN201680026628.6A patent/CN107635577A/zh active Pending
- 2016-05-26 MX MX2017013384A patent/MX2017013384A/es unknown
- 2016-05-26 AU AU2016268389A patent/AU2016268389A1/en not_active Abandoned
- 2016-05-26 KR KR1020177031775A patent/KR20180006376A/ko not_active Application Discontinuation
- 2016-05-26 CA CA2979940A patent/CA2979940A1/en not_active Abandoned
- 2016-05-26 EA EA201792130A patent/EA201792130A1/ru unknown
- 2016-05-26 JP JP2017552120A patent/JP6877356B2/ja active Active
- 2016-05-26 BR BR112017025142A patent/BR112017025142A2/pt not_active IP Right Cessation
-
2018
- 2018-07-19 HK HK18109356.9A patent/HK1249863A1/zh unknown
-
2019
- 2019-10-03 US US16/592,554 patent/US20210128701A1/en not_active Abandoned
-
2021
- 2021-04-27 JP JP2021074695A patent/JP2021138699A/ja active Pending
-
2022
- 2022-05-26 AU AU2022203572A patent/AU2022203572A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3302533A1 (en) | 2018-04-11 |
| WO2016191565A1 (en) | 2016-12-01 |
| US20180110842A1 (en) | 2018-04-26 |
| KR20180006376A (ko) | 2018-01-17 |
| CA2979940A1 (en) | 2016-12-01 |
| AU2016268389A1 (en) | 2017-09-28 |
| AU2022203572A1 (en) | 2022-06-16 |
| GB201510870D0 (en) | 2015-08-05 |
| US20210128701A1 (en) | 2021-05-06 |
| EA201792130A1 (ru) | 2018-04-30 |
| BR112017025142A2 (pt) | 2018-08-07 |
| JP2018516855A (ja) | 2018-06-28 |
| JP2021138699A (ja) | 2021-09-16 |
| CN107635577A (zh) | 2018-01-26 |
| HK1249863A1 (zh) | 2018-11-16 |
| JP6877356B2 (ja) | 2021-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016070166A3 (en) | Messenger una molecules and uses thereof | |
| WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
| PH12015502539A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| ZA201700196B (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| PH12016502430A1 (en) | Method for decreasing immunogenicity of protein and peptide | |
| EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
| MY178445A (en) | Novel antibody binding to tfpi and composition comprising the same | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| AU2018256669A1 (en) | Combination therapy | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| CA3010788A1 (en) | Methods of administering vasopressors | |
| MX2017001461A (es) | Terapia de combinacion. | |
| WO2015156674A3 (en) | Method for treating cancer | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| MX2017013384A (es) | Composiciones que comprenden adamts13 para el uso en metodos para la recanalizacion de los vasos sanguineos ocluidos en un infarto. | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| MX2023005014A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| WO2015200768A3 (en) | Pharmacologic treatments of menière's disease | |
| IN2013MU03428A (es) | ||
| PH12017501918A1 (en) | Multi-peptide composition | |
| Nikonova et al. | APPLICATION OF STANDARDS OF RENDERING MEDICAL CARE IN VERSATILE HOSPITAL | |
| UA92939U (uk) | Фармацевтична композиція | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. |